Rubella Vaccines
A Global Strategic Business Report
MCP35693
WHAT'S BEHIND OUR DATA?
140857226
DOMAIN TRANSCRIPTS6080276
BRANDS TRACKED1729341
FEATURED COMPANIES22574
TOPICS COVERED82719
MARKET SEGMENTS91
KEY INDUSTRIES1574
CURATION TEAM4761909
DECISION MAKERSEXECUTIVE ENGAGEMENTS BY TIER (55)
3
CXO5
VICE PRESIDENT10
DIRECTOR25
MANAGER12
MARKETING
REQUEST FULL-STACK INDEX
Includes 350+ pages validated sources
QUESTIONNAIRE
EXECUTIVES
DATA ROOM
HIGHLIGHTS & REPORT INDEX
Global Rubella Vaccines Market to Reach US$221.1 Million by 2030
The global market for Rubella Vaccines estimated at US$186.7 Million in the year 2024, is expected to reach US$221.1 Million by 2030, growing at a CAGR of 2.9% over the analysis period 2024-2030. Monovalent Formulation, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$95.3 Million by the end of the analysis period. Growth in the Measles-Rubella Vaccine segment is estimated at 1.4% CAGR over the analysis period.
The U.S. Market is Estimated at US$50.9 Million While China is Forecast to Grow at 5.6% CAGR
The Rubella Vaccines market in the U.S. is estimated at US$50.9 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$43.6 Million by the year 2030 trailing a CAGR of 5.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.0% and 2.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.6% CAGR.
Global "Rubella Vaccines" Market – Key Trends & Drivers Summarized
Why Does Rubella Vaccination Remain a Public Health Priority Globally?
Rubella, often mild in children and adults, poses a devastating threat to unborn children when pregnant women become infected, leading to congenital rubella syndrome (CRS). The most effective way to prevent CRS is widespread rubella vaccination, particularly through the measles-mumps-rubella (MMR) combined vaccine. Immunization programs have made remarkable progress in reducing rubella incidence globally, yet gaps remain—especially in regions with weak healthcare infrastructure or vaccine hesitancy. The importance of rubella vaccination lies not only in controlling the virus but also in reducing long-term disabilities caused by CRS. Global campaigns coordinated by WHO and UNICEF aim to integrate rubella into universal MMR coverage by 2030. High-income countries have nearly eliminated rubella, while parts of Africa and Southeast Asia are scaling up efforts through mass vaccination campaigns and maternal health programs.
Are Combination Vaccines and New Logistics Models Broadening Access?
The widespread use of MMR and MR (measles-rubella) combination vaccines has simplified immunization schedules and enhanced coverage. These multivalent vaccines reduce clinic visits, cut storage needs, and increase compliance. Innovations like micro-needle patches, intradermal injectors, and thermostable formulations are addressing last-mile delivery challenges. Additionally, collaborative initiatives with Gavi are enabling low-income countries to receive subsidized MMR doses along with training for healthcare workers. Vaccine stockpile strategies, cold chain expansion, and mobile health units are also improving outreach in remote communities. These developments are not only increasing rubella vaccine penetration but also enabling more consistent integration into routine immunization schedules, especially for infants and adolescent girls.
Can Surveillance and Serological Testing Help Eliminate Rubella Globally?
Surveillance and lab testing are critical in verifying rubella elimination and identifying regions at risk. Real-time monitoring systems, supported by digital registries and lab networks, enable prompt detection of outbreaks and CRS cases. Serological surveys help assess population immunity, guiding targeted immunization drives. Countries like Japan, the UK, and South Korea have leveraged comprehensive surveillance data to fine-tune their vaccination strategies, especially for adult men who may have missed childhood immunization. Surveillance also aids in understanding vaccine efficacy over time, helping health systems plan booster campaigns if needed. The harmonization of rubella surveillance with measles elimination programs offers a synergistic pathway to achieving dual viral control under shared public health frameworks.
What’s Powering the Expansion of Rubella Vaccination Across Health Systems?
The growth in the global rubella vaccines market is driven by several factors including rising global birth rates, increasing integration of combination vaccines, and stronger public health mandates. National immunization programs, particularly in Asia-Pacific, Africa, and Latin America, are scaling up MMR/MR vaccine delivery through both routine and supplemental immunization activities. Regulatory approvals of newer MR variants and regional manufacturing initiatives are boosting local availability and reducing costs. Strategic partnerships between international health agencies and vaccine producers are enhancing delivery infrastructure. Moreover, public health messaging and maternal screening programs are increasing rubella awareness among healthcare providers and women of childbearing age. Digital health systems are helping track immunization coverage and flag gaps in high-risk populations, further
SCOPE OF STUDY
The report analyzes the Rubella Vaccines market by the following Segments, and Geographic Regions/Countries:
Segments:
Type (Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine, Measles Mumps Rubella Varicella Vaccine); End-Use (Hospitals, NGOs, Pediatric Clinics, Other End-Uses).
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa..
SELECT PLAYERS
Abbott Laboratories; AstraZeneca plc; Bavarian Nordic; Bharat Biotech; Biological E. Limited; Cadila Healthcare (Zydus Cadila); Chumakov Federal Scientific Center; CSL Seqirus; GlaxoSmithKline plc; Haffkine Bio-Pharmaceutical Corporation Ltd.; Indian Immunologicals Limited; Institute of Poliomyelitis and Viral Encephalitides; Merck & Co., Inc.; Panacea Biotec Ltd.; Pfizer Inc.; Sanofi S.A.; Serum Institute of India Pvt. Ltd.; Sinovac Biotech Ltd.; Takeda Pharmaceutical Company Limited; Wockhardt Ltd.
AI INTEGRATIONS
We’re transforming market and competitive intelligence with validated expert content and AI tools.
Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
TABLE OF CONTENTS
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy |
| World Market Trajectories |
| How Trump’s Tariffs Impact the Market? The Big Question on Everyone’s Mind |
| Rubella Vaccines – Global Key Competitors Percentage Market Share in 2025 (E) |
| Competitive Market Presence - Strong/Active/Niche/Trivial for 32 Players Worldwide in 2025 (E) |
| 2. FOCUS ON SELECT PLAYERS |
| 3. MARKET TRENDS & DRIVERS |
| Global Focus on Eradication of Congenital Rubella Syndrome Drives Vaccination Efforts |
| Integration of Rubella with Measles and Mumps Vaccines Expands Market Reach |
| WHO and UNICEF Campaigns Propel Coverage in Low- and Middle-Income Countries |
| National Immunization Programs Reinforce Market Demand for Rubella-Containing Vaccines |
| Increased Availability of Combination Vaccines Simplifies Public Health Deployment |
| School Entry Mandates and Routine Immunization Policies Sustain Pediatric Demand |
| Improved Cold Chain Infrastructure Supports Widespread Vaccine Distribution |
| Rising Seroprevalence Studies Highlight Gaps in Immunity and Drive Catch-Up Campaigns |
| Regulatory Approvals for Combination Formulations Enhance Procurement Appeal |
| Ongoing Public Health Surveillance Throws the Spotlight on Outbreak Prevention Strategies |
| Private Sector Participation in Immunization Clinics Generates Supplemental Demand |
| Global Health Goals and SDG Targets Accelerate Government Commitments |
| Innovations in Thermostable Vaccines Expand Access in Rural and Remote Regions |
| Growing Support for Adolescent and Adult Immunization Policies Expands Demographic Reach |
| Donor and NGO Funding Channels Create New Avenues for Market Expansion |
| 4. GLOBAL MARKET PERSPECTIVE |
| World Rubella Vaccines Market Analysis of Annual Sales in US$ for Years 2015 through 2030 |
| World Recent Past, Current & Future Analysis for Rubella Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR |
| World Historic Review for Rubella Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| World 15-Year Perspective for Rubella Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030 |
| World Recent Past, Current & Future Analysis for Monovalent Formulation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR |
| World Historic Review for Monovalent Formulation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| World 15-Year Perspective for Monovalent Formulation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030 |
| World Recent Past, Current & Future Analysis for Measles-Rubella Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR |
| World Historic Review for Measles-Rubella Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| World 15-Year Perspective for Measles-Rubella Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030 |
| World Recent Past, Current & Future Analysis for Measles / Mumps / Rubella Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR |
| World Historic Review for Measles / Mumps / Rubella Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| World 15-Year Perspective for Measles / Mumps / Rubella Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030 |
| World Recent Past, Current & Future Analysis for Measles Mumps Rubella Varicella Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR |
| World Historic Review for Measles Mumps Rubella Varicella Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| World 15-Year Perspective for Measles Mumps Rubella Varicella Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030 |
| World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR |
| World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030 |
| World Recent Past, Current & Future Analysis for NGOs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR |
| World Historic Review for NGOs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| World 15-Year Perspective for NGOs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030 |
| World Recent Past, Current & Future Analysis for Pediatric Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR |
| World Historic Review for Pediatric Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| World 15-Year Perspective for Pediatric Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030 |
| World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR |
| World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030 |
| III. MARKET ANALYSIS |
| UNITED STATES |
| Rubella Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E) |
| USA Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR |
| USA Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| USA 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030 |
| USA Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR |
| USA Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| USA 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030 |
| CANADA |
| Canada Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR |
| Canada Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| Canada 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030 |
| Canada Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR |
| Canada Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| Canada 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030 |
| JAPAN |
| Rubella Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E) |
| Japan Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR |
| Japan Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| Japan 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030 |
| Japan Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR |
| Japan Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| Japan 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030 |
| CHINA |
| Rubella Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E) |
| China Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR |
| China Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| China 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030 |
| China Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR |
| China Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| China 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030 |
| EUROPE |
| Rubella Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E) |
| Europe Recent Past, Current & Future Analysis for Rubella Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR |
| Europe Historic Review for Rubella Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| Europe 15-Year Perspective for Rubella Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030 |
| Europe Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR |
| Europe Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| Europe 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030 |
| Europe Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR |
| Europe Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| Europe 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030 |
| FRANCE |
| Rubella Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E) |
| France Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR |
| France Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| France 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030 |
| France Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR |
| France Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| France 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030 |
| GERMANY |
| Rubella Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E) |
| Germany Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR |
| Germany Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| Germany 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030 |
| Germany Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR |
| Germany Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| Germany 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030 |
| ITALY |
| Italy Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR |
| Italy Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| Italy 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030 |
| Italy Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR |
| Italy Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| Italy 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030 |
| UNITED KINGDOM |
| Rubella Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E) |
| UK Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR |
| UK Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| UK 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030 |
| UK Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR |
| UK Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| UK 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030 |
| SPAIN |
| Spain Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR |
| Spain Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| Spain 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030 |
| Spain Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR |
| Spain Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| Spain 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030 |
| RUSSIA |
| Russia Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR |
| Russia Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| Russia 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030 |
| Russia Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR |
| Russia Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| Russia 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030 |
| REST OF EUROPE |
| Rest of Europe Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR |
| Rest of Europe Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| Rest of Europe 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030 |
| Rest of Europe Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR |
| Rest of Europe Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| Rest of Europe 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030 |
| ASIA-PACIFIC |
| Rubella Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E) |
| Asia-Pacific Recent Past, Current & Future Analysis for Rubella Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR |
| Asia-Pacific Historic Review for Rubella Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| Asia-Pacific 15-Year Perspective for Rubella Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030 |
| Asia-Pacific Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR |
| Asia-Pacific Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| Asia-Pacific 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030 |
| Asia-Pacific Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR |
| Asia-Pacific Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| Asia-Pacific 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030 |
| AUSTRALIA |
| Rubella Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E) |
| Australia Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR |
| Australia Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| Australia 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030 |
| Australia Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR |
| Australia Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| Australia 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030 |
| INDIA |
| Rubella Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E) |
| India Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR |
| India Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| India 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030 |
| India Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR |
| India Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| India 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030 |
| SOUTH KOREA |
| South Korea Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR |
| South Korea Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| South Korea 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030 |
| South Korea Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR |
| South Korea Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| South Korea 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030 |
| REST OF ASIA-PACIFIC |
| Rest of Asia-Pacific Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR |
| Rest of Asia-Pacific Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| Rest of Asia-Pacific 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030 |
| Rest of Asia-Pacific Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR |
| Rest of Asia-Pacific Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| Rest of Asia-Pacific 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030 |
| LATIN AMERICA |
| Rubella Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E) |
| Latin America Recent Past, Current & Future Analysis for Rubella Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR |
| Latin America Historic Review for Rubella Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| Latin America 15-Year Perspective for Rubella Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030 |
| Latin America Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR |
| Latin America Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| Latin America 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030 |
| Latin America Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR |
| Latin America Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| Latin America 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030 |
| ARGENTINA |
| Argentina Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR |
| Argentina Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| Argentina 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030 |
| Argentina Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR |
| Argentina Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| Argentina 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030 |
| BRAZIL |
| Brazil Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR |
| Brazil Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| Brazil 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030 |
| Brazil Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR |
| Brazil Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| Brazil 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030 |
| MEXICO |
| Mexico Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR |
| Mexico Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| Mexico 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030 |
| Mexico Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR |
| Mexico Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| Mexico 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030 |
| REST OF LATIN AMERICA |
| Rest of Latin America Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR |
| Rest of Latin America Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| Rest of Latin America 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030 |
| Rest of Latin America Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR |
| Rest of Latin America Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| Rest of Latin America 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030 |
| MIDDLE EAST |
| Rubella Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E) |
| Middle East Recent Past, Current & Future Analysis for Rubella Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR |
| Middle East Historic Review for Rubella Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| Middle East 15-Year Perspective for Rubella Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030 |
| Middle East Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR |
| Middle East Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| Middle East 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030 |
| Middle East Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR |
| Middle East Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| Middle East 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030 |
| IRAN |
| Iran Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR |
| Iran Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| Iran 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030 |
| Iran Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR |
| Iran Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| Iran 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030 |
| ISRAEL |
| Israel Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR |
| Israel Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| Israel 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030 |
| Israel Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR |
| Israel Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| Israel 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030 |
| SAUDI ARABIA |
| Saudi Arabia Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR |
| Saudi Arabia Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| Saudi Arabia 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030 |
| Saudi Arabia Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR |
| Saudi Arabia Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| Saudi Arabia 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030 |
| UNITED ARAB EMIRATES |
| UAE Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR |
| UAE Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| UAE 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030 |
| UAE Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR |
| UAE Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| UAE 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030 |
| REST OF MIDDLE EAST |
| Rest of Middle East Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR |
| Rest of Middle East Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| Rest of Middle East 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030 |
| Rest of Middle East Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR |
| Rest of Middle East Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| Rest of Middle East 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030 |
| AFRICA |
| Rubella Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E) |
| Africa Recent Past, Current & Future Analysis for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR |
| Africa Historic Review for Rubella Vaccines by Type - Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| Africa 15-Year Perspective for Rubella Vaccines by Type - Percentage Breakdown of Value Sales for Monovalent Formulation, Measles-Rubella Vaccine, Measles / Mumps / Rubella Vaccine and Measles Mumps Rubella Varicella Vaccine for the Years 2015, 2025 & 2030 |
| Africa Recent Past, Current & Future Analysis for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR |
| Africa Historic Review for Rubella Vaccines by End-Use - Hospitals, NGOs, Pediatric Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2015 through 2023 and % CAGR |
| Africa 15-Year Perspective for Rubella Vaccines by End-Use - Percentage Breakdown of Value Sales for Hospitals, NGOs, Pediatric Clinics and Other End-Uses for the Years 2015, 2025 & 2030 |
COMPETITIVE METRICS
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: [email protected]